Share of R&D spending in revenue of Jiangsu Hengrui Pharmaceuticals 2016-2022
In 2022, the Chinese pharmaceutical giant Jiangsu Hengrui Pharmaceuticals spent more than 6.3 billion yuan on research and development, representing almost 30 percent of its overall operating income. As the leading developer of oncology medicine, the company's R&D spending increased by more than 400 percent since 2016.